Your browser doesn't support javascript.
loading
Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.
Kunacheewa, Chutima; Feng, Lei; Manasanch, Elisabet E; Bashir, Qaiser; Patel, Krina K; Mehta, Rohtesh; Kaufman, Gregory P; Srour, Samer; Saini, Neeraj; Iyer, Swaminathan P; Thomas, Sheeba K; Weber, Donna M; Orlowski, Robert Z; Qazilbash, Muzaffar H; Lee, Hans C.
Afiliación
  • Kunacheewa C; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Manasanch EE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bashir Q; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel KK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mehta R; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kaufman GP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Srour S; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Saini N; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Iyer SP; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Thomas SK; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Weber DM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Orlowski RZ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Qazilbash MH; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee HC; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Br J Haematol ; 193(3): e23-e26, 2021 05.
Article en En | MEDLINE | ID: mdl-33748943
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Quimioterapia de Mantención / Lenalidomida / Mieloma Múltiple Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trasplante de Células Madre Hematopoyéticas / Quimioterapia de Mantención / Lenalidomida / Mieloma Múltiple Tipo de estudio: Observational_studies / Prognostic_studies Límite: Female / Humans / Male / Middle aged Idioma: En Revista: Br J Haematol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos